Teva bails from OncoGenex custirsen deal; paying $27m
This article was originally published in Scrip
Executive Summary
Teva will start 2015 by returning the rights to OncoGenex for custirsen, which failed a Phase III metastatic castrate-resistant prostate cancer study this past spring.
You may also be interested in...
Is It The End For OncoGenex? Custirsen Fails In Second Phase III Prostate Cancer Trial
Custirsen, the lead drug candidate from OncoGenex, failed in a second Phase III clinical trial – a trial that may have represented the company's last, best hope of success.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.